Association of the Caveolin Gene with Insulin Resistance and Hypertension

Caveolin 基因与胰岛素抵抗和高血压的关联

• 批准号: 7611458
• 负责人: Patricia Crowley Underwood
• 金额: $ 4.1万
• 依托单位: BOSTON COLLEGE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-19 至 2010-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7611458
• 关键词: Address; Affect; Alleles; Bacteria; Blood Vessels; CAV1 gene; Candidate Disease Gene; Caveolae; Caveolins; Cell membrane; Chronic Disease; Condition; Confounding Factors (Epidemiology); Control Groups; Development; Disease; Distant; Ensure; Fever; Fostering; Frequencies; Functional disorder; Future; Genes; Genetic; Genetic Markers; Genetic Polymorphism; Genomics; Goals; Gold; Hereditary Disease; Homozygote; Hypertension; Individual; Insulin; Insulin Receptor; Insulin Resistance; Measures; Membrane Lipids; Methods; Minor; Morbidity - disease rate; National Institute of Nursing Research; Nurses; Participant; Patients; Phenotype; Population Study; Prevalence; Prevention; Prevention intervention; Process; Public Health; Renin; Research; Research Design; Risk; Role; Scaffolding Protein; Scientist; Secondary to; Signal Transduction; Site; Specific qualifier value; Standards of Weights and Measures; Subcategory; Susceptibility Gene; Technology; Testing; Variant; base; caveolin 1; concept; design; extracellular; innovation; insulin signaling; low renin hypertension; mortality; novel; response; size; therapy design; treatment planning; treatment program

DESCRIPTION (provided by applicant): The long term objective of this proposal is to use genomic technology to individualize prevention and treatment strategies for the heterogeneous disorder hypertension thereby, decreasing the morbidity and mortality that often results from this condition. Specifically, this proposal seeks to identify genomic markers for a homogeneous subset (intermediate phenotype) of hypertension; insulin resistance in hypertension. This objective is consistent with the National Institute of Nursing Research's goal to identify susceptibility genes for at-risk individuals for the design of interventions to moderate risk. The specific aim of this proposal is to determine if polymorphisms in the caveolin gene (Cav-1) are associated with insulin resistance in nonmodulating hypertension (an intermediate phenotype of hypertension). This aim will be analyzed in a three step process. First, participants with homogeneous subsets of hypertension (intermediate phenotypes) will be identified, ensuring a well-defined study population by removing the many confounding variables often present in studies analyzing heterogeneous genetic disorders. Second, a candidate gene, Cav-1, will be analyzed to determine whether polymorphic changes in the gene are associated with a specific homogeneous subset of hypertension. This candidate gene was chosen secondary to its mechanism of action and involvement with insulin signaling and vascular function. Third, insulin resistance will be measured using a euglycemic insulin clamp to determine if participants identified as having the homogeneous subset of hypertension and polymorphic variants of the Cav-1 gene are insulin resistant. Two groups of equal size (non-modulating hypertension versus low-renin hypertension) will be compared to determine whether a significant difference exists between the two groups for both Cav-1 polymorphism frequencies and insulin resistance. A correlation analysis will determine whether an association exists between Cav-1 polymorphisms and insulin resistance in hypertension. The results of this proposed study will advance our understanding of the genetic underpinnings of insulin resistance and hypertension, potentially altering current approaches to chronic illnesses, Specifically, genetic information related to insulin resistance and hypertension will foster future research to develop and implement nurse led, patient specific rather than the current non-specific interventions for the prevention and treatment of the chronic illness hypertension. These study findings could directly affect public health by reducing the morbidity and mortality resulting from hypertension. Specifically, through the development of individualized treatment programs, better compliance will likely be achieved.

描述（由申请人提供）：本提案的长期目标是利用基因组技术为异质性高血压疾病提供个性化的预防和治疗策略，从而降低这种疾病通常导致的发病率和死亡率。具体而言，本提案旨在确定高血压同质亚群（中间表型）的基因组标记；高血压的胰岛素抵抗。这一目标与国家护理研究所的目标一致，即确定高危个体的易感基因，以设计干预措施以降低风险。该建议的具体目的是确定小窝蛋白基因（Cav-1）的多态性是否与非调节性高血压（高血压的中间表型）的胰岛素抵抗相关。这一目标将分三步进行分析。首先，将确定具有均匀性高血压亚群（中间表型）的参与者，通过消除分析异质遗传疾病的研究中经常出现的许多混杂变量，确保明确的研究人群。其次，将分析候选基因Cav-1，以确定该基因的多态性变化是否与特定的同质高血压亚群相关。该候选基因的选择是次要的，因为它的作用机制和参与胰岛素信号和血管功能。第三，胰岛素抵抗将使用正糖胰岛素钳测量，以确定具有均匀性高血压亚群和Cav-1基因多态性变异的参与者是否具有胰岛素抵抗。将比较两个大小相等的组（非调节性高血压和低肾素高血压），以确定两组之间Cav-1多态性频率和胰岛素抵抗是否存在显著差异。相关分析将确定Cav-1多态性与高血压患者胰岛素抵抗之间是否存在关联。这项研究的结果将促进我们对胰岛素抵抗和高血压的遗传基础的理解，有可能改变目前对慢性疾病的治疗方法，特别是，与胰岛素抵抗和高血压相关的遗传信息将促进未来的研究，以开发和实施护士主导的，患者特异性的干预措施，而不是目前的非特异性干预措施，以预防和治疗慢性疾病高血压。这些研究结果可以通过降低高血压引起的发病率和死亡率直接影响公众健康。具体来说，通过制定个性化的治疗方案，可能会达到更好的依从性。